What disease does Denosumab treat?

Denosumab is a drug used to treat bone-related diseases. Its main indications include the management of osteoporosis and cancer bone metastases.

1.Treatment of Osteoporosis: Osteoporosis is a bone disease characterized by decreased bone density, bone thinning, and a significantly increased risk of fracture. This disease particularly affects menopausal women and the elderly. Desosumab increases bone density by inhibiting the activity of bone cells (osteoclasts) during the bone resorption process, thereby reducing the risk of fractures and improving patients' bone health.

2.Treatment of cancer bone metastasis: In some cancers, malignant tumor cells can spread into bone tissue, causing cancer bone metastasis. This condition often causes severe bone pain, fractures, and other bone-related problems. The mechanism of action of denosumab can slow or reduce the progression of bone metastases, reduce the risk of fractures, and relieve bone pain, thereby improving the quality of life of cancer patients.

Denosumab is a monoclonal antibody that works by interfering with RANKL (receptor-activated nuclear factor κB ligand), a key molecule in the bone resorption process. This drug targets RANKL and prevents it from binding to bone cells, thereby inhibiting the bone resorption process, increasing bone density, and reducing the risk of fractures.

The generic drug Desosomet is already on the market in China and has been included in medical insurance. Patients can purchase it domestically at a price of about 1,600 yuan. Please consult the local hospital pharmacy or medical insurance bureau for specific prices and reimbursement policies. There are only denosumab original drugs available abroad, mainly the Turkish version of the American Amgen original drug. The price is about 1,300 yuan, and the ingredients and efficacy are consistent with the domestic original drug.